Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT

https://doi.org/10.20996/1819-6446-2018-14-2-235-243

Full Text:

Abstract

Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test their knowledge of the basic provisions of the current recommendations on antiplatelet therapy.

Material and methods. As a material for the study the results of an anonymous questionnaire in randomly selected doctors were used. The questionnaire contained 11 questions concerning the use of antiplatelet agents for primary and secondary prevention of cardiovascular diseases. 276 questionnaires filled out by 185 therapists, 84 cardiologists and 7 physicians of other therapeutic specialties were analyzed.

Results. The results of the study reflect the doctor’s tendency to use acetylsalicylic acid for the primary prevention of cardiovascular diseases, including the patients who do not have indications for its prescribing. 11.6% of respondents never recommend acetylsalicylic acid for primary prevention of cardiovascular diseases. 22.8% of doctors don’t consider it necessary to stop acetylsalicylic acid in patients who do not have indications for such treatment. Therapists demonstrate very low adherence to recommendations which underline the need for a weighted approach to the acetylsalicylic acid prescription. Cardiologists less often than therapists recommend acetylsalicylic acid for the primary prevention of cardiovascular disease in patients with low cardiovascular risk. Less than 30% of therapists and cardiologists tend to prescribe gastroprotectors to patients with aspirin-induced gastropathy. Only 19.6% of the respondents correctly indicated the P2Y12 receptor inhibitor dose to be used in combination with acetylsalicylic acid on the 1st day of acute coronary syndrome depending on planed treatment strategy. 88.4% of doctors consider the use of antiplatelet agents, if the patient with atrial fibrillation and a high risk of thromboembolism refused to take oral anticoagulants. 51.8% of respondents recommend a combination of acetylsalicylic acid and clopidogrel for such patients. Cardiologists are better informed about the recommendations regarding the use of dual antiplatelet therapy and a combination of antiplatelet agents with oral anticoagulants. However, in general, doctors' knowledge of combined antithrombotic therapy is inadequate.

Conclusion. The results of the study show that it is necessary to discuss current recommendations on the use of antiplatelet agents for the primary and secondary prevention of cardiovascular diseases in the context of continuous medical education more actively.

About the Authors

N. В. Perepech
Saint Petersburg State University
Russian Federation

Nikita B. Perepech – MD, PhD, Professor, Head of Clinical, Research and Education Center "Cardioilogy"

Universitetskaya nab. 7-9, St. Petersburg, 199034



A. V. Tregubov
Saint Petersburg State University
Russian Federation

Aleksey V. Tregubov – MD, Junior Researcher, Clinical, Research and Education Center "Cardioilogy"

Universitetskaya nab. 7-9, St. Petersburg, 199034



References

1. Popova L.V., Bokarev I.N. The use of antiplatelet agents in clinical practice. Prakticheskaja Medicina. 2014;6(82):22-8. (In Russ.)

2. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003. doi: 10.1093/eurheartj/eht296.

3. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi: 10.1714/2729.27821.

4. Aboyans V., Ricco J-B., Bartelink M-L. E. L. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Eur Heart J. 2017;00:1-60. doi:10.1093/eurheartj/ehx095.

5. Halvorsen S, Andreotti F, ten Berg J.M. et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention. A Position Paper of the European Society of Cardiology Working Group on Thrombosis. JACC. 2014;64:319-27. doi: 10.1016/j.jacc.2014.03.049.

6. Vandvik P.O., Lincoff A.M., Gore J.M. et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S-668S. doi: 10.1378/chest.11-2306.

7. Bibbins-Domingo K. U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(12):1-22. doi:10.7326/M16-0577.

8. Roffi M., Patrono C., Collet J.P. et al. 2015ESCGuidelines for the management of acutecoronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of AcuteCoronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320.

9. Steg Ph.G., James S.R., Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.

10. Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 101093/eurheartj/ehx393.

11. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi: 101093/eurheartj/ehx419.

12. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(38):2893-962.doi: 10.1093/eurheartj/ehw210

13. Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1

14. Kelly J.P., Kaufman D.W., Jurgelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348(9039):1413-6. doi: 10.1016/S0140-6736(96)01254-8

15. Rostom A., Moayyedi P., Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481-96. doi: 10.1111/j.1365-2036.2008.03905.

16. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi: 10.1056/NEJMoa0904327.

17. Wiviott S.D., Braunwald E., McCabie C.H. et al., for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):200115. doi: 10.1056/NEJMoa0706482.

18. Sulimov V.A., Golicyn S.P., Panchenko E.P. et al. Diagnosis and treatment of atrial fibrillation. Russian Journal of Cardiology. 2013;(4s3):5-100. (In Russ.)


For citation:


Perepech N.В., Tregubov A.V. DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT. Rational Pharmacotherapy in Cardiology. 2018;14(2):235-243. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-2-235-243

Views: 207


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)